anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates generally to the generation of antibodies to cell-surface receptors and cancer-associated proteins, and particularly to such receptors or proteins with cysteine rich regions or cysteine loops. Cell-surface receptors and cancer-associated proteins with cysteine rich regions or cysteine loops and suitable in this invention include EGFR and EGFR family members, insulin receptor, and tyrosine kinases such as IGFR, Ret and Ror. A method is provided generally for the generation of modulators or binders, including antibodies, to cancer associated proteins, particularly cell-surface receptors, which may, particularly in cancers or on amplification or overexpression or other tumorigenic states, display epitopes not necessarily available in correctly folded and processed proteins (wild type or normal situations). Mutant or modified such receptors or proteins, wherein the cysteine rich regions or cysteine loops are altered, or wherein the conformation of the receptor or protein is altered, serve as targets for isolating or screening modulators, including as epitopes for generating antibodies, particularly antibodies which prefer or are specific for a cancer-associated or tumorigenic form(s) of the protein or receptor. The invention also relates to the use of the altered cell-surface receptors or cancer-associated proteins in generating modulators including antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against the altered cell-surface receptors or cancer-associated proteins, including EGFR and EGFR family members.
Polyphosphate activates the intrinsic pathway of coagulation that also induces inflammation. Hypercoagulable and hyperinflammatory challenge are mediators contributing to endothelial dysfunction, organ failure and death, which occur in many pathological conditions. Upon platelet activation, Polyphosphate is released into the microenvironment, where it has been shown to promote coagulation and act as a proinflammatory molecule. The inventors have found that platelet- sized polyphosphate promotes migration of fibroblasts, and also induces smooth muscle actin expression and the formation of stress fibers in fibroblasts, both of which are hallmarks of myofibroblast differentiation. Myofibroblasts play roles in driving both wound healing and fibrosis. This work suggests that polyphosphate not only promotes early wound healing through enhancing fibrin clot formation, but also may play a role in the later stages of wound healing and potentially the progression of fibrotic diseases by recruiting and inducing the differentiation of fibroblasts into myofibroblasts. As such, polyphosphates can be targeted by inhibitors for the treatment of aberrant/pathologic fibrosis, such as anti-polyphosphate antibodies and polyphosphatase enzymes, as well as used as biomarkers for diagnosis, prognosis, and treatment response indicators to provide guidance for treatment plans.
The investigators will purposively select N=20 youth with at least 6 youth from each of 3 age ranges (10-12, 13-15, and 16-18) from eligible participants. Youth will use the software in their home environment for 12-weeks. Youth's diabetes device data will be used to select simulation content, targeted to meet each participant's educational needs. Youth will meet with research staff via video chat at the onset of testing where a URL link to the platform will be shared. Youth will be assigned 3 scenarios/week. At the end of each scenario youth are guided to additional resources in the platform that they may choose to access. Youth will meet with a member of the research team via video chat or phone call weekly to discuss platform issues or confusion as well as any questions regarding self-management content. Platform performance will be monitored by researchers and performance data will be collected and stored within the application database.

Feasibility measures will include recruitment, weekly research sessions attendance, and global attrition data. Sustained engagement measures will be collected from the application database and will include the frequency platform was accessed, number of assigned simulations completed (3 per week), and additional, optional, content accessed. Glycemic control measures including A1C will be obtained from the youth's EHR. Youth's diabetes devices will be downloaded at baseline and at 4, 6 and 12 weeks. Glucose values from device downloads will be aggregated into derived measures of glucose control consistent with American Diabetes Association guidelines on glucose targets. Self-management patterns and responsiveness will be assessed using pre- and post- diabetes device downloads at baseline, 4, 8, and 12 weeks.
• Hypersensitivity to any component of this product. Adverse reactions may include anaphylactic reaction, urticaria, facial and/or tongue swelling, or pruritus. Discontinue cyclobenzaprine hydrochloride extended-release capsules if a hypersensitivity reaction is suspected.  
• Concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after their discontinuation. Hyperpyretic crisis seizures and deaths have occurred in patients receiving cyclobenzaprine (or structurally similar tricyclic antidepressants) concomitantly with MAO inhibitor drugs.  
• During the acute recovery phase of myocardial infarction, and in patients with arrhythmias, heart block or conduction disturbances, or congestive heart failure.  
• Hyperthyroidism.
Four ascending dose levels of placebo (n=8) for intravenous injection for once. Dosage day is Day 1.
Women clear zolpidem tartrate from the body at a lower rate than men. Cmax and AUC parameters of zolpidem from AMBIEN CR were, respectively, approximately 50% and 75% higher at the same dose in adult female subjects compared to adult male subjects. Between 6 and 12 hours after dosing, zolpidem concentrations were 2 to 3 fold higher in adult female compared to adult male subjects. Given the higher blood levels of zolpidem tartrate in women compared to men at a given dose, the recommended initial dose of AMBIEN CR for adult women is 6.25 mg, and the recommended dose for adult men is 6.25 or 12.5 mg.

In geriatric patients, clearance of zolpidem is similar in men and women. The recommended dose of AMBIEN CR in geriatric patients is 6.25 mg regardless of gender.
Lung cancer is the most common cause of cancer death for both men and women in the industrialized world. Small cell lung cancer accounts for about 25% of lung cancers and is usually widespread when it first presents. The remaining 75% of lung cancers are collectively termed non-small cell lung cancers. When presentation is by symptoms or incidental discovery, about 50 to 60% of non-small cell lung cancers are parenchymal nodules or masses and 40 to 50% are bronchial or hilar. More than 50% of patients with non-small cell cancer will have distant metastases at the time of diagnosis and only 25% will be potentially resectable for cure.1 Overall survival at five years for lung cancer is approximately 15% and has not significantly improved over the last several decades. Prognosis for lung cancer is affected by many factors but one of the most important is the stage of the disease at presentation. Individuals with peripheral lesions less than 3 cm in diameter (T1) at presentation are ideal candidates for surgical resection and have the best outcomes, with 5-year survival rates as high as 60 to 80%.2 Patients with small subcentimeter pulmonary nodes may have even better survival with resection. Computed tomography can now detect cancers less than 4 mm in diameter, and it has been shown that resection of subcentimetre lung cancers results in a survival rate of up to 85%.3 However, Suzuki et al found 54% of 92 patients undergoing video assisted thoracoscopic excision of subcentimetre nodules, required conversion to a thoracotomy. Forty percent of those nodules were found to be malignant.4 The most common reason for this conversion was failure to localize the nodule using thoracoscopic visualization or palpation. Furthermore, univariate and multivariate analysis of eleven variables revealed that if the distance from the pleural surface was greater than 5 mm, the probability of failure to detect the nodule was 63%.
Non-smokers, ages 18-80, diagnosed with Progressive Supranuclear Palsy. Must meet the NINDS-SPSP criteria for probable PSP, which requires vertical supranuclear gaze palsy, prominent postural instability, and falls in the first year of onset, as well as a number of other clinical features.
Acute esophageal necrosis (AEN), known as black oesophagus or Gurvit's syndrome, is an extremely rare clinical syndrome. Patients usually present with life-threatening symptoms of upper gastrointestinal haemorrhage (70-90% of cases), as in this case report. Diagnosis of AEN is confirmed based on oesophagogastroduodenoscopy which reveals diffuse or patchy circumferential black necrotic oesophageal mucosa. The presented patient had some comorbidities, such as poorly controlled diabetes mellitus, secondary to chronic pancreatitis, hypertension, after cholecystectomy, addiction to alcohol and tobacco, and taking a small spoon of baking soda three times a day for a few months because of heartburn. Despite the poor prognosis of AEN, with mortality about 32-35%, most patients present with endoscopic improvement in short time - from 7 days to 1 month. Fortunately, the patient did not to have any complications in the course of AEN, and the treatment was effective.
Kidney transplant recipients replacing MMF/MPA by everolimus for at least six weeks, receiving the monovalent Omicron XBB.1.5 COVID-19 mRNA vaccine (Comirnaty, I.M.). Optional to receive the Recombinant Zoster Vaccine (Shingrix, I.M.).
The invention discloses a separation and purification method of tribulus terrestris saponin. The method comprises the steps that a raw material is cleaned, and fed in from a feeding hopper; an extraction tank unit host rotates to slowly push the material from the front end of a unit backwards; an extraction solvent enters an extraction tank from a liquid inlet tube at the tail end of the unit, passes through the moving material from the back end of the tank, and flows towards the front end; and solid and liquid substances are contacted fully in an inverse motion, so that effective components in the medicinal material are extracted. Dregs are forcibly pushed to a dreg discharge port by a discharge transport and then discharged; a special juice squeezer squeezes the dregs; residual medicine liquor in the dregs is squeezed out of a medicinal material tissue; and the content of the residual medicine liquor in the dregs is reduced. The extraction efficiency is higher, and the extraction is more complete. In addition, the method adopts macroporous resin, and is combined with a silica gel column chromatography, so that a separating effect is better. The finished tribulus terrestris saponin with a maximum yield of 2% and the content of above 95% can be obtained.
Instill one drop of CYSTADROPS in each eye, 4 times a day during waking hours.

Do not touch dropper tip to the eyelids, surrounding areas, or any surface, as this may contaminate the solution.

In case of concomitant therapy with other topical ocular products, an interval of 10 minutes should be allowed between successive applications. Eye ointments should be administered last. 

If the patient misses an instillation, the patient should be told to administer a dose as soon as feasible and then continue the treatment with the next scheduled instillation. Discard bottle 7 days after first opening.
A radiographic guide is prepared before CT/CBCT scan. The CT/CBCT scan DICOM ﬁles are loaded in GuideMia program and converted into 3D computer images. A surgical template is fabricated through this virtual planning.
Liver resection is the mainstay of curative treatment for hepatocellular carcinoma (HCC). However, recurrence is common after surgery and most occurs in the liver, especially for the patients with high risk factors for residual tumor, such as tumors with a diameter more than 5 cm, multiple nodules, and microvascular invasion. Transarterial chemoembolisation (TACE) is an effective palliative treatment for HCC. It involves the infusion of chemotherapeutic agent admixed with iodised oil followed by embolisation of the hepatic arterial flow using small particles. This procedures allows application of smaller dose of chemotherapy concentrated to the liver and thus is well tolerated with minimal side effects. The main complications of TACE are liver function damage, mild feverish symptoms, vomit , etc. But most of them are reversible.

We conduct a randomised controlled trial evaluating the efficacy of using TACE after hepatectomy in HCC patients with high risk factors for residual tumor (tumors with a diameter more than 5 cm, multiple nodules, or microvascular invasion).
The invention relates to a specially-shaped bloster used behind the legs. The specially-shaped bloster comprises a yang-side cushion body and a yin-side cushion body. The yang-side cushion body and the yin-side cushion body are the same in shape and size and are both trapezoidal blocks, the top of the yang-side cushion body and the top of the yin-side cushion body are respectively in the shape of an arc saddle, and one vertical lateral wall of the yang-side cushion body is movably connected with one vertical lateral wall of the yin-side cushion body. A two-way yang tonifying regulation object is embedded and fixedly arranged in the middle of the top wall of the yang-side underlay body, and a two-way yin nourishing regulation object is embedded and fixedly arranged in the middle of the top wall of the yin-side cushion body. A yang-side magnetic sheet and a yin-side magnetic sheet are embedded into the upper middle portions of the inclined lateral walls of the same sides of the yang-side cushion body and the yin-side cushion body, an N pole of the yang-side magnetic sheet faces the outer portion of the yang-side cushion body, and an S pole of the yin-side magnetic sheet faces the outer portion of the yin-side cushion body. The specially-shaped bloster has the advantages of being simple in structure, low in production cost, free of energy consumption and capable of relieving lumbago caused by waist and leg imbalance.
Participants will receive the Osia 3 and Osia® 2 sound processors. They will then complete a series of assessments designed to evaluate the clinical performance of these two sound processors. These assessments will take place across four study visits.
Subacute ruminal acidosis (SARA) is a common nutritional metabolic disease in ruminants that causes significant economic losses to dairy farming. Strontium (Sr) is known to be involved in bone metabolism and exhibits potent anti-inflammatory effects. To evaluate the effect of Sr on inflammation in bovine ruminal epithelial cells, a model of LPS-induced inflammation was established in this study, and the cell viability of bovine ruminal epithelial cells was measured using CCK-8. The production of pro-inflammatory cytokines was measured by ELISA and real-time PCR, respectively. The related proteins of the TLR4/MyD88/NF-κB pathway were assayed through Western blotting, and the fluorescence of p-p65 and p-IκB were assayed by immunofluorescence. Molecular docking of Sr and TLR4/MyD88/NF-κB pathway-related proteins was performed using MIB2 ( http://bioinfo.cmu.edu.tw/MIB2/ ). Results showed that after treatment for 24 h, the cell viability was decreased at the high concentration of Sr (≥ 10 mmol/L). Sr significantly decreased the production of TNF-α, IL-1β, and IL-6, downregulated the related proteins expression of the TLR4/MyD88/NF-κB pathway, and reduced the fluorescence levels of p-p65 and p-IκB. The NF-κB pathway inhibitor PDTC and molecular docking further revealed that Sr reduced LPS-induced pro-inflammatory cytokines production via the TLR4/MyD88/NF-κB pathway. These results suggest that Sr reduces LPS-induced pro-inflammatory cytokines production via the TLR4/MyD88/NF-κB pathway, thereby exerting an anti-inflammatory effect in bovine ruminal epithelial cells, providing a basis for Sr in the treatment of bovine rumen acidosis disease.
Patients receive LGX818 PO QD and MEK162 PO BID continuously for 8 weeks followed by intermittent dosing in subsequent cycles (3 weeks off therapy, 5 weeks on therapy). Cycles repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.
A clotting serum production device including a main chamber, an inlet housing, and an outlet port. The main chamber is defined by a first end wall, a second end wall opposite to the first end wall, and a side wall extending between the first end wall and the second end wall. The inlet housing extends from the first end wall. The inlet housing includes a first inlet port, a second inlet port, and a first conduit extending between the first inlet port and a second conduit. The second conduit extends between the second inlet port and the main chamber. The inlet housing is configured to provide one-way fluid flow from the first inlet port to the second inlet port and to provide one-way fluid flow from the second inlet port to the main chamber. An outlet port is in fluid communication with the main chamber and provides fluid communication with an exterior of the clotting serum production device.
The invention provides a separate H9N2 avian influenza virus. A genome of the H9N2 avian influenza virus is composed of RNA fragments shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8. The invention further provides a vaccine used for preventing the H9N2 avian influenza virus and a preparation method of the vaccine. The preparation method includes the steps that vaccine antigen liquid is prepared, and the toxic value is measured; the antigen liquid is inactivated; oil phase adjuvant is prepared; a vaccine aqueous phase is prepared; the vaccine is prepared. By inoculating the vaccine, infection of the antigen group D H9N2 avian influenza virus can be prevented. By using an antibody, infection of the antigen group D H9N2 avian influenza virus can be treated.
Subjects will receive placebo for 16 Weeks. Subjects who achieve certain predefined response criteria will proceed with placebo until Week 56. Subjects who do not achieve certain predefined response criteria will enter the bimekizumab escape arm.
BACKGROUND AND AIMS: The causal relationship between gut microbiota and gout and hyperuricemia (HUA) has not been clarified. The objective of this research was to evaluate the potential causal effects of gut microbiota on HUA and gout using a two-sample Mendelian randomization (MR) approach.
METHODS AND RESULTS: Genetic instruments were selected using summary statistics from genome-wide association studies (GWASs) comprising a substantial number of individuals, including 18,473 participants for gut microbiome, 288,649 for serum urate (SU), and 763,813 for gout. Two-sample MR analyses were performed to determine the possible causal associations of gut microbial genera with the risk of HUA and gout using the inverse-variance weighted (IVW) method, and robustness of the results was confirmed by several sensitivity analyses. A reverse MR analysis was conducted on the bacterial taxa that were identified in forward MR analysis. Based on the results of MR analyses, Escherichia-Shigella (OR = 1.05; 95% CI, 1.01-1.08; P = 0.009) exhibited a positive association with SU levels, while Lachnospiraceae NC2004 group (OR = 0.95; 95% CI, 0.92-0.98; P = 0.001) and Family XIII AD3011 group (OR = 0.94; 95% CI, 0.90-0.99; P = 0.015) were associated with a reduced HUA risk. Moreover, Coprococcus 3 (OR = 1.17, 95% CI: 1.01-1.34, P = 0.031) was causally associated with a higher gout risk. In reverse MR analysis, no causal relationships were identified between these bacterial genera and HUA or gout.
CONCLUSION: This study provides evidence for a causal association between gut microbial genera and HUA or gout, and further investigations of the underlying mechanism are warranted.
PURPOSE:An immunological activating agent, containing xanthan gum as an active constitutent, capable of enhancing the immonulogocal activity of a living body, destroying or checking the growth of cancerous cells, and effective for the viral or bacterial infectious diseases without side effects. CONSTITUTION:An immunological activating agent containing xanthan gum as an active constituent. The xanthan gum consists of glucose, mannose and glucuronic acid as main constitutent saccharides, and is considered to be a straight chain polysaccharide in which the respective constituent saccharides are linked by the beta-linkages and mannose is joined to the glucose at a regular interval as a side chain, and used as a food additive without any toxicity. Furthermore, the xanthan gum is not capable of directly destroying cancerous cells but enhancing the immunological activity of a living body in administration thereto. The activated immunological activity is capable of destroying or checking the growth of the cancerous cells. The very low toxicity of the xanthan gum permits the administration to the living body in a large amount and therefore the immunological activation for a long term. The dose thereof about is 10-10,000mg/ kg/ day.
FIELD: medicine, chemical- -pharmaceutical industry, pharmacy. SUBSTANCE: invention relates to pharmaceutical composition eliciting cytokine and immunomodulating effect used for prophylaxis and treatment of diseases caused by disorders of immunologic functions. Addition of copolymer of 1,4-ethylenepiperazine N-oxide and (N-carboxyethyl)-1,4-ethylenepiperazinium bromide to an active substance in pharmaceutical composition consisting of at least one cytokine or conjugation with the latter allows creating the novel immunotherapeutic preparation with the enhanced effectiveness as compared with the known analogs. Advantage of invention involves the creation of preparation eliciting ability to modulate cytokine effect and it comprises new additional biological properties also. EFFECT: enhanced effectiveness of composition, valuable medicinal properties. 9 tbl, 8 ex
CA-LINC is a 90-day culturally adapted LINC intervention developed with and for Black youth. The CA-LINC intervention integrates engagement and follow-up strategies to assess/monitor suicide risk, facilitate service use referrals/linkages, develop/reﬁne safety plans, and create villages of care. The CA-LINC intervention incorporates African-centered principles and empowerment and motivational strategies to support, enhance strengths, promote hope, improve family relationships, and reinforce caring messages. This consumer-, community-, and theory-driven care coordination intervention is designed to reduce suicide ideation and behavior (SIB) by improving service engagement and delivery standards. CA-LINC is implemented by Peer Support Specialists and Community Health Workers assigned to mental health "hubs" in Black Faith Based Organizations (FBOs) to facilitate standardization and access to care.
Mindfulness-Based Stress Reduction (MBSR) is a program intended to draw upon the group's shared experiences to facilitate the development of mindfulness. MBSR is offered in 2.5-h classes on a weekly basis for 8 consecutive weeks, with a retreat day in between classes 6 and 7. This day involves guided meditations, allowing for continuity in practice. Classes include specific exercises (e.g. identifying thoughts, emotions and body sensations associated with illness); these are then extended as homework and discussed in the subsequent class. The curriculum themes and content are arranged week by week to reflect these principles.